新的研究发现,DARZALEX FASPRO大大降低了在高风险发霉的多种骨髓瘤中的累进风险。 New study finds DARZALEX FASPRO® significantly reduces progression risk in high-risk smoldering multiple myeloma.

一项新的研究表明,DARZALEX FASPRO药物可以大大减少高风险熔化多处间皮瘤到活性多处间皮瘤的风险。 A new study shows that the drug DARZALEX FASPRO® can significantly reduce the risk of high-risk smoldering multiple myeloma progressing to active multiple myeloma. 与标准监测相比,药物存活率提高了,推迟了进一步治疗的需要。 Compared to standard monitoring, the drug improved survival rates and delayed the need for further treatment. 这项研究在ASH年度会议上作了介绍,目前正在考虑更广泛地批准该药物,以便治疗高危险发霉性骨髓瘤。 The study was presented at the ASH Annual Meeting, and the drug is now being considered for broader approval for treating high-risk smoldering myeloma.